Durability of Heterologous and Homologous COVID-19 Vaccine Boosts

Chen Sabrina Tan; Ai‐ris Y. Collier; Jingyou Yu; Jinyan Liu; Abishek Chandrashekar; Katherine McMahan; Catherine Jacob-Dolan; Xuan He; Vicky Roy; Blake M. Hauser; Jennifer E. Munt; Michael L. Mallory; Melissa D. Mattocks; John M. Powers; Rita M. Meganck; Marjorie Rowe; Rachel Hemond; Esther A. Bondzie; Kate Jaegle; Ralph S. Baric; Aaron G. Schmidt; Galit Alter; Mathieu Le Gars; Jerald Sadoff; Dan H. Barouch

doi:10.1001/jamanetworkopen.2022.26335

Key Points

To assess the durability of humoral and cellular immune responses following heterologous versus homologous COVID-19 vaccine boosting.
Monitored immune durability in individuals who received a primary BNT162b2 vaccine series followed by a heterologous Ad26.COV2.S booster.
Measured and compared humoral (antibody) and cellular (T-cell) immune response profiles.
Heterologous boosting with Ad26.COV2.S elicited durable humoral and cellular immune responses in individuals previously vaccinated with BNT162b2.
Heterologous prime-boost regimens demonstrated sustained immunological advantages over homologous schedules for SARS-CoV-2 protection.

Ask about this paper

Answers are grounded in this paper and cite their sources.

Implication

Comparative study demonstrates durable humoral and cellular immunity in BNT162b2 recipients boosted with Ad26.COV2.S, suggesting clear benefits of heterologous prime-boost regimens.

Abstract

Heterologous Ad26.COV2.S boosting was associated with durable humoral and cellular immune responses in individuals who originally received the BNT162b2 vaccine. These data suggest potential benefits of heterologous prime-boost vaccine regimens for SARS-CoV-2.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Tan et al. (2022) studied this question.

synapsesocial.com/papers/69d9a16d5e5bcb4e3b837457 https://doi.org/10.1001/jamanetworkopen.2022.26335

View Full Paper

Ask AI

Bookmark

Share

Durability of Heterologous and Homologous COVID-19 Vaccine Boosts

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Durability of Heterologous and Homologous COVID-19 Vaccine Boosts

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading